“This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website.”
CombiGene and Cell and Gene Therapy Catapult sign agreement to develop manufacturing process for novel gene therapy to treat epilepsy
Collaboration between Cell and Gene Therapy Catapult (CGT Catapult) and Swedish gene therapy company CombiGene will take a unique therapy one step closer to helping sufferers of hard to treat epilepsy. Read more >> Combigene AB, Medicon Village,...read more
Another gene therapy product, Luxturna from Sparks Therapeutics, was approved December 19 by the FDA, the US food and drug regulatory authority. This clearly demonstrates what potential gene therapy has. Read more >> Combigene AB, Medicon Village,...read more
Study with brain tissue from human epilepsy patients confirms that brain cells express CombiGene’s candidate drug CG01
CombiGene has, in collaboration with Associate Professor David Woldbye at University of Copenhagen and Professor Merab Kokaia at Lund University, carried out a so-called ”human expression study”, i.e. a study using brain tissue from human epilepsy...read more
Initial data from the long-term study on CombiGene’s candidate drug for treating epilepsy indicate positive effects in the form of fewer seizures.
Initial data from CombiGene’s preclinical proof-of-concept-study (the long-term study) show that CombiGene’s candidate drug, CG01, has antiepileptic effects. The study has demonstrated that CG01 reduces the frequency of epileptic seizures in...read more